D.C. Court Backs FDA’s Decision on Narcolepsy Drug Amid Jazz Pharmaceuticals’ Challenge
In a recent decision, a D.C. federal judge upheld the U.S. Food and Drug Administration’s determination regarding a narcolepsy treatment by ruling that it is not the “same drug” as Jazz Pharmaceuticals’ exclusive treatment. This ruling supports the FDA’s approval process of the rival drug as compliant with the stipulations of the Orphan Drug Act….